PET Imaging Agent Identifies Recurrent Prostate Cancer
|
By MedImaging International staff writers Posted on 07 Apr 2017 |
|
Image: A PET scan of recurrent prostate tumor with fluciclovine (L) compared to indium-111 (R) in same region (Photo courtesy of Radiology).
A diagnostic agent for positron emission tomography (PET) imaging can help identify suspected sites of prostate cancer recurrence.
Axumin (fluciclovine) is a synthetic L-leucine analogue radiolabeled with fluorine 18 (18F), which enters cells via amino acid transporters. Since tumor cells exhibit enhanced amino acid transport in order to help them access the materials they need to grow and spread, they take up Axumin more than healthy tissues, providing physicians with a better tool for locating recurrent prostate cancer sites, based on a detected rise in the levels of prostate specific antigen (PSA) following initial therapy.
Axumin has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron during the PET scan. The distribution of Axumin in the body also differs from other tracers, with a low native brain uptake compared to Fludeoxyglucose (FDG). Axumin is a product of Blue Earth Diagnostics, and has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
“An imaging agent with sufficient diagnostic performance to adequately detect and localize recurrent prostate cancer can provide referring physicians with actionable information to guide biopsy, and inform management decisions for their patients,” said David Schuster, MD, director of the division of nuclear medicine and molecular imaging at Emory University (Atlanta, GA, USA). “The product will be convenient for patients and imaging facilities, as it can be made widely available and the entire imaging procedure can typically be completed in less than 30 minutes.”
A variety of imaging techniques and tests are currently used to diagnose and monitor prostate cancer, including PSA blood tests, magnetic resonance imaging (MRI), PET, SPECT, and CT scans. Each method has strengths and weaknesses, but there is no single method that is able to successfully identify and monitor primary tumors, metastatic lymph nodes, and bone lesions, which can cause the patient to undergo unnecessary treatments or painful biopsies.
Axumin (fluciclovine) is a synthetic L-leucine analogue radiolabeled with fluorine 18 (18F), which enters cells via amino acid transporters. Since tumor cells exhibit enhanced amino acid transport in order to help them access the materials they need to grow and spread, they take up Axumin more than healthy tissues, providing physicians with a better tool for locating recurrent prostate cancer sites, based on a detected rise in the levels of prostate specific antigen (PSA) following initial therapy.
Axumin has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron during the PET scan. The distribution of Axumin in the body also differs from other tracers, with a low native brain uptake compared to Fludeoxyglucose (FDG). Axumin is a product of Blue Earth Diagnostics, and has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
“An imaging agent with sufficient diagnostic performance to adequately detect and localize recurrent prostate cancer can provide referring physicians with actionable information to guide biopsy, and inform management decisions for their patients,” said David Schuster, MD, director of the division of nuclear medicine and molecular imaging at Emory University (Atlanta, GA, USA). “The product will be convenient for patients and imaging facilities, as it can be made widely available and the entire imaging procedure can typically be completed in less than 30 minutes.”
A variety of imaging techniques and tests are currently used to diagnose and monitor prostate cancer, including PSA blood tests, magnetic resonance imaging (MRI), PET, SPECT, and CT scans. Each method has strengths and weaknesses, but there is no single method that is able to successfully identify and monitor primary tumors, metastatic lymph nodes, and bone lesions, which can cause the patient to undergo unnecessary treatments or painful biopsies.
Post-Processing Imaging System
DynaCAD Prostate
Biopsy Software
Affirm® Contrast
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Digital Intelligent Ferromagnetic Detector
Digital Ferromagnetic Detector
Latest Radiography News
- X-Ray Breakthrough Captures Three Image-Contrast Types in Single Shot
- AI Generates Future Knee X-Rays to Predict Osteoarthritis Progression Risk
- AI Algorithm Uses Mammograms to Accurately Predict Cardiovascular Risk in Women
- AI Hybrid Strategy Improves Mammogram Interpretation
- AI Technology Predicts Personalized Five-Year Risk of Developing Breast Cancer
- RSNA AI Challenge Models Can Independently Interpret Mammograms
- New Technique Combines X-Ray Imaging and Radar for Safer Cancer Diagnosis
- New AI Tool Helps Doctors Read Chest X‑Rays Better
- Wearable X-Ray Imaging Detecting Fabric to Provide On-The-Go Diagnostic Scanning
- AI Helps Radiologists Spot More Lesions in Mammograms
- AI Detects Fatty Liver Disease from Chest X-Rays
- AI Detects Hidden Heart Disease in Existing CT Chest Scans
- Ultra-Lightweight AI Model Runs Without GPU to Break Barriers in Lung Cancer Diagnosis
- AI Radiology Tool Identifies Life-Threatening Conditions in Milliseconds
- Machine Learning Algorithm Identifies Cardiovascular Risk from Routine Bone Density Scans
- AI Improves Early Detection of Interval Breast Cancers
Channels
MRI
view channel
Novel Imaging Approach to Improve Treatment for Spinal Cord Injuries
Vascular dysfunction in the spinal cord contributes to multiple neurological conditions, including traumatic injuries and degenerative cervical myelopathy, where reduced blood flow can lead to progressive... Read more
AI-Assisted Model Enhances MRI Heart Scans
A cardiac MRI can reveal critical information about the heart’s function and any abnormalities, but traditional scans take 30 to 90 minutes and often suffer from poor image quality due to patient movement.... Read more
AI Model Outperforms Doctors at Identifying Patients Most At-Risk of Cardiac Arrest
Hypertrophic cardiomyopathy is one of the most common inherited heart conditions and a leading cause of sudden cardiac death in young individuals and athletes. While many patients live normal lives, some... Read more
Ultrasound
view channel
Wearable Ultrasound Imaging System to Enable Real-Time Disease Monitoring
Chronic conditions such as hypertension and heart failure require close monitoring, yet today’s ultrasound imaging is largely confined to hospitals and short, episodic scans. This reactive model limits... Read more
Ultrasound Technique Visualizes Deep Blood Vessels in 3D Without Contrast Agents
Producing clear 3D images of deep blood vessels has long been difficult without relying on contrast agents, CT scans, or MRI. Standard ultrasound typically provides only 2D cross-sections, limiting clinicians’... Read more
Nuclear Medicine
view channel
PET Imaging of Inflammation Predicts Recovery and Guides Therapy After Heart Attack
Acute myocardial infarction can trigger lasting heart damage, yet clinicians still lack reliable tools to identify which patients will regain function and which may develop heart failure.... Read more
Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers
Aggressive cancers such as osteosarcoma and glioblastoma often resist standard therapies, thrive in hostile tumor environments, and recur despite surgery, radiation, or chemotherapy. These tumors also... Read more
New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer
Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more
General/Advanced Imaging
view channel
New Algorithm Dramatically Speeds Up Stroke Detection Scans
When patients arrive at emergency rooms with stroke symptoms, clinicians must rapidly determine whether the cause is a blood clot or a brain bleed, as treatment decisions depend on this distinction.... Read more
3D Scanning Approach Enables Ultra-Precise Brain Surgery
Precise navigation is critical in neurosurgery, yet even small alignment errors can affect outcomes when operating deep within the brain. A new 3D surface-scanning approach now provides a radiation-free... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
GE HealthCare (Chicago, IL, USA) has entered into a collaboration with NVIDIA (Santa Clara, CA, USA), expanding the existing relationship between the two companies to focus on pioneering innovation in... Read more
Patient-Specific 3D-Printed Phantoms Transform CT Imaging
New research has highlighted how anatomically precise, patient-specific 3D-printed phantoms are proving to be scalable, cost-effective, and efficient tools in the development of new CT scan algorithms... Read more
Siemens and Sectra Collaborate on Enhancing Radiology Workflows
Siemens Healthineers (Forchheim, Germany) and Sectra (Linköping, Sweden) have entered into a collaboration aimed at enhancing radiologists' diagnostic capabilities and, in turn, improving patient care... Read more